Myasthenia Gravis
179
53
61
69
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
21 trials with published results (12%)
Research Maturity
69 completed trials (39% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
10 terminated out of 179 trials
87.3%
+0.8% vs benchmark
12%
21 trials in Phase 3/4
30%
21 of 69 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 69 completed trials
Clinical Trials (179)
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
MuSK Myasthenia 1000 Study
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Biomarkers in Autoimmune Disease of Nervous System
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Capturing Key MG-symptoms Using Smartphone Recordings.
Interventions Against Fatigue in Patients With Myasthenia Gravis
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
A Study in Patients With Myasthenia Gravis in China